“We believe the strong patient protections in Part D will help everyone get access to the drugs that are right for them at a lower cost,” Mr Azar said during a recent speech, “but we want your input on how that should work.”
Comorbidities like hepatitis C virus, renal, liver, and chronic pulmonary diseases significantly boosted the risk of hospitalization and costs of patients with HIV, a recent study suggests.
The International Antiviral Society–USA Panel has released a set of updated recommendations for the treatment of patients with HIV, including universal screening for anyone who has been sexually active and rapid start for all eligible newly diagnosed patients.
According to a new study in The American Journal of Managed Care, less restrictive formulary designs, which allow patients with HIV to initiate potentially safer and more efficacious regimens, result in better outcomes and cost reductions.
Two recent trials published in The Lancet HIV found that adults with HIV who switched from dolutegravir-abacavir-lamivudine or from boosted protease inhibitor-based regimens to a fixed-dose of Biktarvy (bictegravir-emtricitabine-tenofovir; Gilead) maintained virologic suppression.